Beijing Tiantan Biological Products Corp Ltd
SSE:600161

Watchlist Manager
Beijing Tiantan Biological Products Corp Ltd Logo
Beijing Tiantan Biological Products Corp Ltd
SSE:600161
Watchlist
Price: 20.52 CNY -1.2% Market Closed
Market Cap: 40.6B CNY
Have any thoughts about
Beijing Tiantan Biological Products Corp Ltd?
Write Note
Beijing Tiantan Biological Products Corp Ltd
/
Income Statement
/
Net Income (Common)

Beijing Tiantan Biological Products Corp Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Beijing Tiantan Biological Products Corp Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Beijing Tiantan Biological Products Corp Ltd
SSE:600161
Net Income (Common)
¥1.3B
CAGR 3-Years
22%
CAGR 5-Years
17%
CAGR 10-Years
16%
Beigene Ltd
HKEX:6160
Net Income (Common)
-¥6.7B
CAGR 3-Years
16%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Net Income (Common)
-¥1.3B
CAGR 3-Years
3%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Net Income (Common)
¥1.2B
CAGR 3-Years
23%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Net Income (Common)
¥3.7B
CAGR 3-Years
-26%
CAGR 5-Years
12%
CAGR 10-Years
39%
Imeik Technology Development Co Ltd
SZSE:300896
Net Income (Common)
¥1.9B
CAGR 3-Years
62%
CAGR 5-Years
72%
CAGR 10-Years
N/A
No Stocks Found

Beijing Tiantan Biological Products Corp Ltd
Glance View

Market Cap
40.6B CNY
Industry
Biotechnology

In the bustling heart of China's biotech industry, Beijing Tiantan Biological Products Corp Ltd emerges as a key player in the crucial field of vaccine and blood product innovations. Rooted in the expansive landscape of pharmaceutical development, the company sets its focus on producing essential vaccines—including those for hepatitis B—and blood-derived products such as albumin, immunoglobulin, and coagulation factor. These products play pivotal roles in preventative healthcare and in treating various diseases. Tiantan Bio operates with a robust integration of research and manufacturing expertise, underpinned by a deep commitment to public health advancement. The company continuously seeks to expand its product offerings, refining processes through relentless research and development to meet the demands of both domestic and international markets. Earnings for Tiantan Biological flow primarily from the successful commercialization of its vaccines and blood products. The company establishes strategic partnerships with research institutions and leverages government healthcare policies that favor domestic vaccine consumption to bolster its market position. Tiantan Bio also invests significantly in infrastructure to upscale its production capabilities, responding to the growing demand for its products. Their business model capitalizes on the symbiotic relationship between research innovation and market needs, ensuring a steady stream of revenue through both public procurement and private healthcare partnerships. This strategic orientation not only showcases its influence in the biotech sphere but also reflects its adaptability and foresight in navigating the dynamic landscape of global healthcare challenges.

Intrinsic Value
25.18 CNY
Undervaluation 19%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Beijing Tiantan Biological Products Corp Ltd's Net Income (Common)?
Net Income (Common)
1.3B CNY

Based on the financial report for Sep 30, 2024, Beijing Tiantan Biological Products Corp Ltd's Net Income (Common) amounts to 1.3B CNY.

What is Beijing Tiantan Biological Products Corp Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
16%

Over the last year, the Net Income (Common) growth was 9%. The average annual Net Income (Common) growth rates for Beijing Tiantan Biological Products Corp Ltd have been 22% over the past three years , 17% over the past five years , and 16% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.